Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) - Trial NCT06133101
Access comprehensive clinical trial information for NCT06133101 through Pure Global AI's free database. This Phase 2 trial is sponsored by Marialena Mouzaki and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 44 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Marialena Mouzaki
Children's Hospital Medical Center, Cincinnati
Timeline & Enrollment
Phase 2
Nov 01, 2023
Jun 01, 2026
Primary Outcome
Change in liver disease severity
Summary
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk
 consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators
 hypothesize that the daily consumption of soy isoflavones found in the soy milk will be
 beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do
 not expect any adverse endocrine or metabolomic effects from the consumption of soy
 isoflavones.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06133101
Non-Device Trial